KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced the results from two pivotal Phase 3 trials (COUGH-1 and COUGH-2) evaluating the ...
*Estimated relative reduction (%) vs placebo was estimated by 1OO*(exp(diff) -1), where diff was the difference provided by the analysis of the log transformed variable. The secondary endpoints in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results